Strategic partnerships EVI actively federates major EU vaccine research entities and expands collaborations with research foundations and CDMOs, presenting recurring co-development and manufacturing opportunities for vaccine candidates and influenza-related products.

Public-private collaborations Recent multi-organization announcements with La Fondation pour la Recherche Scientifique, Naobios, and Nuvonis indicate a readiness to engage in joint development and manufacturing for viral vaccines and challenge agents, signaling potential for contract development and manufacturing partnerships.

Influenza focus The joint efforts to develop an influenza A(H3N2) human viral challenge agent highlight a concrete product development pathway, suggesting sales opportunities in challenge studies, GMP production, and related process development services.

Global NGO footprint As a European PDP with a broad network and funding coordination role, EVI can facilitate access to grant-supported vaccine R&D programs, enabling partners to align on funding, regulatory strategies, and accelerated development milestones.

Tech and data readiness EVI’s use of cloud, data and collaboration tools, plus emphasis on coordinating externally funded consortia, indicates a need for integrated digital solutions, data management, and secure collaboration platforms to support multi-stakeholder vaccine development efforts.